{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:09:53Z","timestamp":1761764993660},"reference-count":84,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.jpsychires.2007.10.007","type":"journal-article","created":{"date-parts":[[2007,12,21]],"date-time":"2007-12-21T17:56:26Z","timestamp":1198259786000},"page":"884-893","source":"Crossref","is-referenced-by-count":36,"title":["Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting"],"prefix":"10.1016","volume":"42","author":[{"given":"Malin","family":"Alenius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Wadelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Hartvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareta","family":"Hammarlund-Udenaes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2007.10.007_bib1","unstructured":"Alenius M, Hartvig P, Lindstr\u00f6m L, Sundquist S, Hammarlund-Udenaes M. Patients with adequate and inadequate treatment response defined from social and clinical needs, drug side effects and previous treatments, CANSEPT."},{"key":"10.1016\/j.jpsychires.2007.10.007_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.154.4.1","article-title":"Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association","volume":"154","author":"APA","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/6.4.577","article-title":"A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia","volume":"6","author":"Arinami","year":"1997","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)91581-4","article-title":"Association of dopamine D2 receptor molecular variant with schizophrenia","volume":"343","author":"Arinami","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.170.1.23","article-title":"Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype","volume":"170","author":"Armstrong","year":"1997","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(95)92168-0","article-title":"Association between clozapine response and allelic variation in 5-HT2A receptor gene","volume":"346","author":"Arranz","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00008571-199812000-00004","article-title":"Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response","volume":"8","author":"Arranz","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/08039480310002075","article-title":"Test\u2013retest reliability of the Camberwell Assessment of Need (CAN)","volume":"57","author":"Arvidsson","year":"2003","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sciences"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/(SICI)1096-8628(19990820)88:4<407::AID-AJMG19>3.0.CO;2-3","article-title":"\u2212141 C del\/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population","volume":"88","author":"Breen","year":"1999","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/schbul\/6.4.606","article-title":"Catamnestic long-term study on the course of life and aging of schizophrenics","volume":"6","author":"Ciompi","year":"1980","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib12","doi-asserted-by":"crossref","first-page":"26013","DOI":"10.1074\/jbc.271.42.26013","article-title":"Functional analysis of the human D2 dopamine receptor missense variants","volume":"271","author":"Cravchik","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-200241070-00001","article-title":"Cytochrome p450 phenotyping\/genotyping in patients receiving antipsychotics: useful aid to prescribing?","volume":"41","author":"Dahl","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib14","first-page":"516","article-title":"Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis","volume":"274","author":"Dahl","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib15","unstructured":"Eriksson L, Pelling H. L\u00e4kemedelsboken, Kapitel om psykoser: Apoteket AB, 2005."},{"key":"10.1016\/j.jpsychires.2007.10.007_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/347773a0","article-title":"Identification of the primary gene defect at the cytochrome P450 CYP2D locus","volume":"347","author":"Gough","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/2.12.2197-a","article-title":"PCR detection of the TaqA RFLP at the DRD2 locus","volume":"2","author":"Grandy","year":"1993","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib18","first-page":"778","article-title":"The human dopamine D2 receptor gene is located on chromosome 11 at q22\u2013q23 and identifies a TaqI RFLP","volume":"45","author":"Grandy","year":"1989","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1600-0447.1995.tb09584.x","article-title":"The assessment of needs in psychiatric patients. Interrater reliability of the Swedish version of the Camberwell Assessment of Needs instrument and results from a cross-sectional study","volume":"92","author":"Hansson","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1176\/ajp.144.6.718","article-title":"The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later","volume":"144","author":"Harding","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/ajp.144.6.727","article-title":"The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia","volume":"144","author":"Harding","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/schbul\/23.2.287","article-title":"Course and outcome for schizophrenia versus other psychotic patients: a longitudinal study","volume":"23","author":"Harrow","year":"1997","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0140-6736(90)92086-W","article-title":"Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification","volume":"336","author":"Heim","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib24","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/clinchem\/46.8.1072","article-title":"Rapid detection of the CYP2D6\u22173, CYP2D6\u22174, and CYP2D6\u22176 alleles by tetra-primer PCR and of the CYP2D6\u22175 allele by multiplex long PCR","volume":"46","author":"Hersberger","year":"2000","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1440-1819.2002.00935.x","article-title":"The influence on the schizophrenic symptoms by the DRD2Ser\/Cys311 and \u2212141C Ins\/Del polymorphisms","volume":"56","author":"Himei","year":"2002","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib26","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.050585397","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajmg.10045","article-title":"Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia","volume":"105","author":"Hori","year":"2001","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/6.4.592","article-title":"Longitudinal studies of schizophrenic patients","volume":"6","author":"Huber","year":"1980","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"4","author":"Jonsson","year":"1999","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib30","first-page":"141","article-title":"T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability","volume":"24","author":"Joober","year":"1999","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.mp.4001054","article-title":"Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia","volume":"7","author":"Kaiser","year":"2002","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl. 64","key":"10.1016\/j.jpsychires.2007.10.007_bib33","first-page":"5","article-title":"Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"12","author":"Kane","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0920-9964(98)00038-3","article-title":"Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia","volume":"32","author":"Kapitany","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDRI gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/geno.1995.1042","article-title":"Identification, expression, and pharmacology of a Cys23\u2013Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)","volume":"27","author":"Lappalainen","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00001756-199901180-00011","article-title":"No evidence for association of serotonin-2A receptor variant (102T\/C) with schizophrenia or clozapine response in a Chinese population","volume":"10","author":"Lin","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica Supplement"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib40","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1176\/appi.ajp.161.5.780","article-title":"Pharmacogenetics of psychotropic drug response","volume":"161","author":"Malhotra","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib41","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(96)91650-5","article-title":"5HT 2a receptor T102C polymorphism and schizophrenia","volume":"347","author":"Malhotra","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib42","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1097\/00001756-199609020-00007","article-title":"Clozapine response and the 5HT2C Cys23Ser polymorphism","volume":"7","author":"Malhotra","year":"1996","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib44","first-page":"587","article-title":"Effects of antipsychotic drugs on serotonin receptors","volume":"43","author":"Meltzer","year":"1991","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ajmg.10602","article-title":"Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding","volume":"114","author":"Mihara","year":"2002","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib46","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1176\/appi.ajp.160.12.2202","article-title":"Long-term course of schizophrenic illness: Bleuler\u2019s study reconsidered","volume":"160","author":"Modestin","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib47","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/archpsyc.61.11.1163","article-title":"Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression","volume":"61","author":"Murphy","year":"2004","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib48","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/humu.20039","article-title":"Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1","volume":"23","author":"Neville","year":"2004","journal-title":"Human Mutation"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib49","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/archpsyc.1991.01810310066012","article-title":"Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism","volume":"48","author":"Noble","year":"1991","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients","volume":"33","author":"Nordstrom","year":"1993","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(95)92756-5","article-title":"Genetic variation of the 5-HT2A receptor and response to clozapine","volume":"346","author":"Nothen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0165-1781(98)00092-4","article-title":"Functional polymorphism of \u2212141C Ins\/Del in the dopamine D2 receptor gene promoter and schizophrenia","volume":"81","author":"Ohara","year":"1998","journal-title":"Psychiatry Research"},{"issue":"Suppl. 60","key":"10.1016\/j.jpsychires.2007.10.007_bib53","first-page":"4","article-title":"The evolving definition of treatment resistance","volume":"12","author":"Peuskens","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib54","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1192\/bjp.167.5.589","article-title":"The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness","volume":"167","author":"Phelan","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib55","first-page":"505","article-title":"The dopamine D2 receptor 5\u2032-flanking variant, \u2212141C Ins\/Del, is not associated with reduced dopamine D2 receptor density in vivo","volume":"9","author":"Pohjalainen","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.mp.4000350","article-title":"The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers","volume":"3","author":"Pohjalainen","year":"1998","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0009-9120(03)00092-4","article-title":"Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects","volume":"36","author":"Saito","year":"2003","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/appi.ajp.158.5.802","article-title":"Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene","volume":"158","author":"Schafer","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jjp.69.399","article-title":"In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used","volume":"69","author":"Schotte","year":"1995","journal-title":"Japanese Journal of Pharmacology"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib60","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib61","first-page":"101","article-title":"Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","article-title":"Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors","volume":"16","author":"Seeman","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.mp.4000842","article-title":"Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia","volume":"6","author":"Segman","year":"2001","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib65","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s002130000521","article-title":"Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility","volume":"152","author":"Segman","year":"2000","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib66","first-page":"1045","article-title":"DRD2 Ser311\/Cys311 polymorphism in schizophrenia","volume":"343","author":"Shaikh","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib67","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1","volume":"348","author":"Siddiqui","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib68","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1528-1167.2005.46304.x","article-title":"Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment","volume":"46","author":"Sills","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib69","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0140-6736(92)91196-F","article-title":"Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson\u2019s disease","volume":"339","author":"Smith","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":"Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib71","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/clinchem\/44.5.914","article-title":"Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication","volume":"44","author":"Steijns","year":"1998","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib72","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00008571-200108000-00009","article-title":"The \u2212141C Ins\/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients","volume":"11","author":"Suzuki","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-200006000-00007","article-title":"The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients","volume":"10","author":"Suzuki","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib74","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-3223(01)01076-9","article-title":"Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor","volume":"50","author":"Tan","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib75","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0924-9338(03)00066-X","article-title":"T102C and \u22121438 G\/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive\u2013compulsive disorder","volume":"18","author":"Tot","year":"2003","journal-title":"European Psychiatry"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/hmg\/2.3.338","article-title":"An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis","volume":"2","author":"Warren","year":"1993","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0447.1996.tb10613.x","article-title":"A prospective 1\u20135 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment","volume":"93","author":"Wieselgren","year":"1996","journal-title":"Acta Psychiatrica Scandinavia"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib80","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(96)90939-3","article-title":"Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group","volume":"347","author":"Williams","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib81","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/0140-6736(90)93163-J","article-title":"Detection of debrisoquine hydroxylation phenotypes","volume":"336","author":"Wolf","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib82","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/009127002401382678","article-title":"Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone","volume":"42","author":"Yasui-Furukori","year":"2002","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","article-title":"Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jpsychires.2007.10.007_bib84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2\u2217A1 allele","volume":"185","author":"Young","year":"2004","journal-title":"British Journal of Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239560700180X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239560700180X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T20:43:23Z","timestamp":1588193003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002239560700180X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S002239560700180X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2007.10.007","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}